Condition: Flumazenil Adverse Reaction · Remimazolam · Hip Joint · Sponsor: Pusan National University Yangsan Hospital
Remimazolam is a medication that has the advantage of a short half-life and reversibility with flumazenil. In clinical situations, the use of flumazenil for the reversal of sedation is common, but there is no precise indication for its administration. In this study, we aim to investigate the necessity of routine flumazenil use after administering remimazolam for intravenous anesthesia.
This description comes directly from the study's public registry record.
Jaesang BAE, MD · 820553602129 · wotkdqo@gmail.com
Always discuss trial participation with your own doctor first.
| Pusan National University Yangsan Hospital | Yangsan, Gyeongsangnam-do, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05939674